Back to catalogue
№ 349 22 filings · 2021-09-28 → 2026-09-25

ROBINSON PLC

RBN
Industrial Goods and Services Share price 123p Market cap £21m Overall fit 165 /1000

Cheap-ish UK small-cap packaging industrial with essentially zero AI-receiver exposure, only moderate operating leverage, decelerating earnings and small-cap AIM illiquidity — a poor fit for an AI-beneficiary + operating-leverage strategy despite a reasonable valuation and property backstop.

Fair value range 100p–145p Mid case · £21m
Absolute upside -0.1% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clear segmental disclosure and audited financials
  • Independently valued surplus property with signed disposals in progress
  • Consistent 6p dividend policy provides an income anchor
Limits the call
  • FY27 dislocated by disclosed contract loss with unquantified mitigation
  • Aggressive 'other items' adjustments make trend earnings power hard to anchor
Methodology

Sum-of-parts: EBIT multiple on operating business plus property realisation less net debt, cross-checked to tangible book

In one line · bull case

Sub-scale AIM packaging manufacturer trading around tangible book with a genuine £7m property backstop and a reset strategy — cheap, but with no AI angle and decelerating operational momentum.

In one line · biggest risk

The disclosed FY27 contract loss (£3.3m revenue / £1.0m gross profit) unmitigated compounds a Polish demand slide and elevated polymer/energy costs, keeping earnings power stuck below the target 6-8% margin.

Drivers
AI beneficiary 5 /100
Custom FMCG packaging manufacturer with no product or revenue linkage to AI infrastructure or agentic-AI adoption.
Operating leverage 45 /100
Moderate: ~20% gross margin, ~£8-9m fixed opex, contribution margin ~30% on incremental volume, but capex-heavy and no software-like drop-through.
Earnings vs expectations 35 /100
Mixed record with 2024 beat, several in-lines, and a clear FY26 guidance cut plus disclosed FY27 contract loss.
Growth momentum 30 /100
Underlying OP guided down from £3.6m (2025) to £2.2-2.6m (2026) and flat into 2027 after customer contract non-renewal.
Moat 25 /100
Custom tooling and long customer relationships give modest switching costs, but repeated contract losses and commoditised HDPE competition point to weak durability.
Earnings quality 45 /100
Frequent 'other items' (impairments, pension buy-out, restructuring, flood, property gains) obscure underlying trend; cash conversion mixed with heavy working capital swings.
Management quality 45 /100
New CEO since Dec 2024 executing sensible restructuring but three CEOs in two years and repeated impairments limit track record.
Cyclicality 45 /100
FMCG end-markets provide staple-like defensiveness but luxury gift and personal care premium volumes are consumer-discretionary; Polish demand notably volatile.
Leverage 35 /100
Net debt £6.4m at H1 2026 (~1x EBITDA), £18.6m facilities, comfortable but rising working capital needs.
Value-trap signals · 5
  • Recurring impairments (Denmark goodwill 2024; plant 2025)
  • Recent guidance cut just three months after AGM reaffirmation
  • Statutory PBT losses in 2023 and 2024 masked by 'underlying' adjustments
  • CEO turnover — three CEOs in roughly two years
  • Structural pricing pressure in Poland and Denmark from customer consolidation and commoditised HDPE

Robinson plc (RBN) — Investment Research Note

Executive summary

Robinson is a small AIM-listed custom manufacturer of injection/blow-moulded plastic and rigid paperboard packaging for FMCG customers (P&G, Unilever, McBride, Bakkavor), with plants in the UK, Poland and Denmark and a legacy portfolio of surplus Chesterfield property being progressively monetised. The five-year trajectory has been volatile — underlying operating profit rebuilt from £1.2m (2021) through £2.0m/£2.2m/£3.2m/£3.6m (2022–25) — but H1 2026 has re-broken the momentum (underlying OP £0.9m vs £2.0m) and management has now guided FY26 to £2.2–2.6m and flagged the non-renewal of a customer contract (£3.3m revenue / £1.0m gross profit) that leaves FY27 profitability "broadly in line with FY26". The single most important valuation point today is that this is a sub-scale, low-margin industrial with a real (but slowly monetising) property backstop trading roughly at operating book value — cheapness is real but so is the earnings-quality drag.

Fair value estimate

Fair value range: ~100p – 145p per share; implied market cap £16.8m – £24.3m; mid ~£20.5m (~123p).

Methodology — sum-of-parts blended with a normalised EBIT multiple, cross-checked to tangible book:

  • Operating business: normalised underlying EBIT of £2.3–2.8m (mid £2.5m, consistent with FY26 guide and the FY27 "flat" indication 2026-09 trading update; 2026-08 interim). Taxed at ~25% and multiplied at 6–8× (small-cap UK industrial packaging peer band) → £11–17m equity value contribution.
  • Surplus property: management-disclosed portfolio value ~£7.4m at 30 June 2025 with c.£3.6m already under exchange/option (Boythorpe £2.85m option; Walton Works £0.6m; further ~£2.2m under offer) 2026-08 interim; 2025-08 interim. Take at £6–8m realisation net of costs.
  • Less net debt of £6.4m at 30 June 2026 2026-08 interim.

Cross-check — tangible net assets £25.7m (153p) with £3m revaluation reserve; underlying 2025 EPS 13.1p on trailing basis (~9× P/E at 120p) but guided to fall to ~7–8p underlying in 2026. A 6% dividend yield at 6p (currently covered ~1.5× on underlying basis) supports the low end.

Latest disclosed mcap £20.1m (120p) sits close to the middle of the range → absolute upside ~+2% to mid, range of roughly ‑17% to +21%. View: fair.

Sector context

Confirmed classification: Industrial Goods and Services / Containers & Packaging (UK small-cap). Robinson sits below sector norms on scale, margin (underlying OP margin ~4–6% vs a 6–8% own target and 8–12% typical for larger packaging peers) and returns; leverage is moderate. Listed comparables: Macfarlane Group (MACF), Coral Products (CRU), and to a lesser extent Mpac Group (MPAC) and European names like Wentworth Resources are less relevant. Macfarlane is the most useful reference on multiple.

Investment thesis

  • Cheap on tangible assets with a monetising property backstop. Trades at ~0.8× tangible book with c.£7.4m of independently valued surplus property (Chesterfield) being sold down — £1.5m realised in H1 2026, further £3.6m under exchange/option, £2.2m under offer 2026-08 interim. Every £1m of proceeds retires debt and de-risks the operating leg.
  • Steady dividend commitment. Total dividend held at 6.0p through the downturn (interim 2.5p reaffirmed Aug 2026), yielding ~5% at 120p, funded through property disposals and underlying cash generation 2026-08 interim; 2026-03 final.
  • Strategic reset under new CEO with a strengthened pipeline in UK PET and Denmark. John Melia (CEO from Dec 2024) has moved from regional to functional structure with new Head of Commercial / Head of Operations, and UK plastics is winning share in PET bottles as customers migrate from HDPE/glass driven by EPR legislation 2026-03 final; 2026-08 interim.

Key risks

  • Recent guidance cut and contract loss point to fragile momentum. FY26 underlying OP now £2.2–2.6m vs £3.6m in 2025; a significant customer contract worth £3.3m revenue / £1.0m gross profit will not renew at Dec 2026, meaning FY27 is guided flat despite the operational base 2026-09 trading update; 2026-08 interim.
  • Poland deterioration and Denmark structural weakness. H1 2026 Polish volumes down 15%; Denmark suffered a £1.7m goodwill/intangible impairment in 2024 tied to a struggling flagship project; local markets are highly commoditised on price 2026-08 interim; 2025-03 final.
  • Input-cost and geopolitical exposure. Middle East disruption has kept polymer/energy/freight costs elevated and constrained material availability; recovery via price is uncertain, and the Paperbox raw-material quality issue added rectification costs in H1 2026 2026-08 interim; 2026-05 AGM statement.

Operating leverage

Robinson displays moderate operating leverage typical of an asset-heavy small-cap manufacturer: gross margin sits at ~20–22% (H1 2026 20%; FY25 22%), depreciation runs ~£3.7m p.a. on £23m PP&E, and underlying operating costs are ~£8–9m of largely fixed overhead (H1 2026 £4.9m, up 18% YoY reflecting new senior hires) 2026-08 interim; 2026-03 final. The company itself quantifies the effect: Poland volumes down 15% drove profit down materially through "operational gearing"; and the disappearing customer contract contributes £1.0m of gross profit on £3.3m of revenue — a ~30% contribution margin at that unit. Applied symmetrically: a 10–20% revenue beat above current expectations (say £5.6–11.2m incremental revenue at 25–30% contribution margin) would add £1.4–3.4m to operating profit — meaningful given a £2.4m base, but not the multi-bagger leverage the "long-tail" investor is looking for. The business does not have the fixed-R&D or SaaS-like drop-through profile of a true operating-leverage story; capex is chunky and ongoing (£4m p.a. installing new moulding machines).

Value-trap signals

  • Repeated pattern of "underlying" profit padded by property disposals and pension items — statutory PBT was a loss in both 2023 and 2024 2025-03 final; 2024-03 final.
  • Recurring impairments (Denmark goodwill 2024, plant impairment 2025 £0.4m) 2025-03 final; 2026-03 final.
  • Guidance cut mid-2026 after the AGM only three months prior had reaffirmed FY26 in line — a de-facto profit warning 2026-05 AGM statement; 2026-08 interim.
  • Structural pressure in Poland (customers reformatting/discontinuing products) and Denmark (commoditised HDPE, historical contract losses).
  • CEO turnover: Roberts resigned Sep 2023 → Interim CEO → Melia Dec 2024 (three CEO transitions in ~2 years).
  • Small-cap AIM illiquidity (16.75m shares, £20m mcap).

Earnings vs. expectations

Reviewing the sequence: FY22 beat prior guidance (OP £2.0m vs modest 2021 base). FY23 — Jan 2024 trading update called profits "in line" with expectations after the Aug 2023 interim had flagged softness; the June 2023 AGM had already contained a de facto warning ("substantially below" H1 profit) and triggered a restructuring 2024-01 trading; 2023-08 interim; 2023-06 AGM. FY24 genuinely beat — Jan 2025 statement said "moderately ahead of current market expectations" and the March 2025 final delivered £3.2m OP vs a £2.5m implied prior view 2025-01 trading; 2025-03 final. H1 2025 / FY25 were in line — FY25 £3.6m as guided 2025-08 interim; 2026-03 final. FY26 — May 2026 AGM said "in line"; August 2026 interim cut the range to £2.2–2.6m (well below the prior implied ~£3.6m); September 2026 update then disclosed the customer contract loss. Pattern: two meets, one beat (2024), and a clear miss/cut in 2026 — trending toward more misses than beats.

Conviction

3 — moderate. Anchors: (i) disclosure is granular by business unit with clear segmental data, (ii) property backstop is independently valued and largely under contract, (iii) financial statements are audited and clean of restatements. Limiters: (i) FY27 has been dislocated by a specific contract loss and the mitigation is unquantified, (ii) the "underlying" adjustment is aggressive across the period (property, pension, flood, restructuring) making trend earnings power hard to pin, and (iii) my terminal multiple is a judgement call — the same numbers support anywhere from 90p to 150p.

Filings consulted · 26

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-25Trading Update2026-09-25_9790281_trading-update.md0.85
  2. 2026-08-20Interim Results2026-08-20_9730770_interim-results.md0.90
  3. 2026-05-21Result OF Agm2026-05-21_9580973_result-of-agm.md0.30
  4. 2026-05-21Agm Trading Statement2026-05-21_9578787_agm-trading-statement.md0.85
  5. 2026-03-05Final Results2026-03-05_9459167_final-results.md0.85
  6. 2025-08-21Interim Results2025-08-21_9066695_interim-results.md0.58
  7. 2025-05-22Result OF Agm2025-05-22_8893218_result-of-agm.md0.20
  8. 2025-05-22Agm Trading Statement2025-05-22_8891225_agm-trading-statement.md0.55
  9. 2025-03-27Final Results2025-03-27_8799430_final-results.md0.65
  10. 2025-01-23Trading Statement2025-01-23_8701789_trading-statement.md0.55
  11. 2024-08-15Interim Results Amp Ceo Appointment2024-08-15_8367559_interim-results-amp-ceo-appointment.md0.41
  12. 2024-05-09Result OF Agm2024-05-09_8186522_result-of-agm.md0.14
  13. 2024-05-09Agm Trading Statement2024-05-09_8184042_agm-trading-statement.md0.38
  14. 2024-03-22Final Results2024-03-22_8101357_final-results.md0.45
  15. 2024-01-18Trading Statement2024-01-18_7994757_trading-statement.md0.38
  16. 2023-08-17Interim Results2023-08-17_7700763_interim-results.md0.23
  17. 2023-06-23Result OF Agm2023-06-23_7590215_result-of-agm.md0.07
  18. 2023-06-22Agm Statement2023-06-22_7587577_agm-statement.md0.10
  19. 2023-03-30Final Results2023-03-30_7377971_final-results.md0.25
  20. 2023-01-24Trading Statement2023-01-24_7499665_trading-statement.md0.21
  21. 2022-09-08Interim Results2022-09-08_7269431_interim-results.md0.23
  22. 2022-05-26Result OF Agm2022-05-26_7028631_result-of-agm.md0.07
  23. 2022-05-26Agm Statement2022-05-26_7026980_agm-statement.md0.10
  24. 2022-03-24Final Results2022-03-24_7049916_final-results.md0.25
  25. 2021-12-09Trading Statement2021-12-09_6793974_trading-statement.md0.21
  26. 2021-09-28Capital Markets Day2021-09-28_6593357_capital-markets-day.md0.10

This research note was authored by a large language model after reading 22 regulatory filings published between 2021-09-28 and 2026-09-25. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.